.jpg)
Annaliesa S. Anderson, PhD, FAAM,
Annaliesa Anderson, PhD, FAAM, has over 20 years of pharmaceutical research experience and is currently the Vice President and Chief Scientific Officer for Bacterial Research, within the Vaccine Research and Development Unit at Pfizer Inc. Her responsibilities include infectious disease vaccine research and development, surveillance, and the assessment of the immunopathology of bacterial colonization and disease. Dr. Anderson’s experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Neisseria meningitidis, staphylococcus aureus and Clostridium difficile. In these roles, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept, and recently the licensure of the N. meningitidis serogroup B vaccine Trumenba®.
Prior to joining Pfizer,
